{
    "clinical_study": {
        "@rank": "122832", 
        "acronym": "REBECCA", 
        "arm_group": {
            "arm_group_label": "Helical tomotherapy for breast cancer", 
            "arm_group_type": "Other", 
            "description": "All women included in REBECCA cohort will be treated with helical tomotherapy for theur breast cancer.\nTheir cardiac follow-up will be based on echocardiography, CT coronary angiogram and blood samples"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether a new technique of radiotherapy for breast\n      cancer (helical tomotherapy) can induce cardiac toxicity that would be detected in the first\n      two years after treatment. Screening of subclinical cardiac lesions with non-invasive\n      cardiac imaging techniques combined with measures of circulating biomarkers of cardiac\n      tissue lesions and coronary lesions would allow assessing radiation-induced cardiac toxicity\n      at an early stage."
        }, 
        "brief_title": "REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity)", 
        "completion_date": {
            "#text": "November 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Toxicity Due to Radiotherapy", 
            "Breast Cancer", 
            "Lesion; Cardiac"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "REBECCA study will consist in a monocentric prospective cohort that will include 120 women\n      volunteers treated with adjuvant tomotherapy for breast cancer in the Institut Regaud\n      Claudius-Toulouse (ICR) and followed for 2 years after radiotherapy.\n\n      In summary, women aged between 40 and 70 years, surgically treated at ICR for breast cancer\n      and for whom adjuvant radiotherapy with tomotherapy is indicated, with no indication of\n      chemotherapy will be eligible for the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women treated surgically for left or right breast cancer and for who adjuvant\n             treatment is radiotherapy with irradiation of the breast or chest wall irradiation\n             and possibly lymph node chains,\n\n          -  Age between 40 and 70 years\n\n          -  Adjuvant Radiotherapy is helical tomotherapy performed at Institut Claudius\n             Regaud(Toulouse, France)\n\n        Exclusion Criteria:\n\n          -  Indication of adjuvant chemotherapy\n\n          -  Clinically or radiologically detectable metastasis\n\n          -  Personal history of coronary artery or myocardial disease\n\n          -  Personal history of breast cancer or other cancer requiring radiotherapy to the chest\n\n          -  Contraindications to injection of iodinated contrast ( for CT ) : pregnancy , renal\n             failure, allergy.\n\n          -  Pregnancy, lactation\n\n          -  Before radiotherapy, LVEF <50%\n\n          -  Before radiotherapy, longitudinal strain > - 16 %\n\n          -  Before radiotherapy,longitudinal strain rate <1% / s\n\n          -  Before radiotherapy, segmental wall motion abnormality\n\n          -  Coronary CT before radiotherapy showing that a therapeutic treatment is required"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079272", 
            "org_study_id": "2013-A00929-36"
        }, 
        "intervention": {
            "arm_group_label": "Helical tomotherapy for breast cancer", 
            "description": "At baseline, before helical tomotherapy is performed, for each included woman will have:\nmeasures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, \u2026, microparticles and miRNA)\ncardiologic examination including echocardiography for measurement of strain and strain rate\na CT coronary angiogram for measurement of coronary plaque indexes\nHelical tomotherapy will be performed for all women included in the cohort.\nAt the end of tomotherapy, follow-up will include:\nmeasures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy\ncardiologic examinations including a echocardiography 6 and 24 months after radiotherapy\nA CT coronary angiogram 24 months after radiotherapy", 
            "intervention_name": "Helical tomotherapy for breast cancer", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tomotherapy", 
            "Breast Cancer", 
            "Heart", 
            "Subclinical cardiac lesions", 
            "Myocardial lesions", 
            "Coronary lesions", 
            "Circulating biomarkers", 
            "Ionizing radiation", 
            "Heart absorbed doses"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "Massabeau.Carole@claudiusregaud.fr", 
                "last_name": "Carole Massabeau, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Toulouse", 
                    "country": "France", 
                    "zip": "31000"
                }, 
                "name": "Institut Claudius Regaud"
            }, 
            "investigator": [
                {
                    "last_name": "Carole Massabeau, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Francoise Izar, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Brigitte De Lafontan, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity): Evaluation of Radiation-induced Cardiotoxicity of Adjuvant Radiotherapy With Tomotherapy for Breast Cancer", 
        "overall_contact": {
            "email": "sophie.jacob@irsn.fr", 
            "last_name": "Sophie Jacob, PhD"
        }, 
        "overall_contact_backup": {
            "email": "Massabeau.Carole@claudiusregaud.fr", 
            "last_name": "Carole Massabeau, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "Institut Claudius Regaud, Toulouse (France)", 
                "last_name": "Carole Massabeau, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut de Radioprotection et de Suret\u00e9 Nucl\u00e9aire, Fontenay-aux-Roses (France)", 
                "last_name": "Marie-Odile Bernier, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital Rangueil, Toulouse (France)", 
                "last_name": "Jean Ferri\u00e8res, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital Rangueil, Toulouse (France)", 
                "last_name": "Herv\u00e9 Rousseau, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome is defined as a decrease of at least 5% in strain or strain rate measures based on cardiac ultrasound exam\"2D strain\" between the measurement before radiotherapy and measures 24 months after radiotherapy and / or an increase of at least 15% in the average index of coronary plaques measured with CT coronary angiogram between the measurement before radiotherapy and measures 24 months after radiotherapy .", 
            "measure": "Number of participants with subclinical cardiac lesions in myocardial levels and/or coronary levels", 
            "safety_issue": "No", 
            "time_frame": "within the first 2 years after tomotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079272"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institut de Radioprotection et de Surete Nucleaire", 
            "investigator_full_name": "Sophie JACOB", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with decrease in myocardial contractility (strain or strain rate measured with cardiac ultrasound exam\"2D strain\")", 
                "safety_issue": "No", 
                "time_frame": "within the first 6 months after tomotherapy"
            }, 
            {
                "measure": "Number of participants with modified measures of circulating biomarkers", 
                "safety_issue": "No", 
                "time_frame": "within the first 2 years after tomotherapy (at the end of radiotherapy, 6 months after radiotherapy and 24 months maximum after radiotherapy)"
            }
        ], 
        "source": "Institut de Radioprotection et de Surete Nucleaire", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Institut Claudius Regaud", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital, Toulouse", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sophie JACOB", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}